Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Regulus Therapeutics Inc (RGLS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Regulus Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.4410 -0.0310    -6.57%
22/10 - Closed. Currency in USD ( Disclaimer )
After Hours
0.4470
+0.0060
+1.3605%
19:22:17 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US75915K2006 
CUSIP:  75915K200
  • Volume: 4,801,502
  • Bid/Ask: 0.4410 / 0.4470
  • Day's Range: 0.4250 - 0.4700
Regulus Therapeutics 0.4410 -0.0310 -6.57%
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

25

Equity Type

ORD

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.

Contact Information

Phone +1-858-2026300
Fax 302-6555049

Top Executives

Name Age Since Title
Thomas H. Tuschl - - Member of the Scientific Advisory Board
Markus Stoffel - - Member of the Scientific Advisory Board
Stelios Papadopoulos 73 2009 Independent Chairman of the Board
David Baltimore 83 2009 Chairman of the Scientific Advisory Board & Independent Director
William H. Rastetter 73 2013 Independent Director
Alice Shih-hou Huang 81 2021 Independent Director
Hugh Rosen 62 2016 Independent Director
Pascale Witz 54 2017 Independent Director
Timothy Michael Wright 65 2016 Member of the Scientific Advisory Board
Simos Efthymios Simeonidis - 2019 Independent Director
Joseph P. Hagan 52 2016 President, CEO & Director
Kathryn J. Collier 53 2018 Independent Director
Jason R. Nunn 51 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RGLS Comments

Write your thoughts about Regulus Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ahmed Almuqayad
Ahmed Almuqayad May 03, 2021 12:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good luck to buy this stock. maybe it will be a Penny stock.
wayne smith
wayne smith Feb 09, 2021 4:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This was a $300 stock, now $1.75, it's gotta long way to go.....
Mbonu Onujiogu
Mbonu Onujiogu Apr 15, 2020 12:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Usually, you won't see a reverse split, when there's high volume of purchase like today. RGLS is at 15% today. Likely, there'll be -3% by tomorrow.
Rajeev Sisodia
Rajeev Sisodia Oct 04, 2018 9:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
reverse split 1:12
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email